BioSig Technologies, Inc. (BSGM) 은(는) 상장 기업입니다 헬스케어 섹터의 Medical - Devices 산업에서 운영. 본사 소재지는 Los Angeles, CT, 미국. 현재 CEO는 Anthony Amato.
BSGM 을(를) 보유 IPO 날짜 2014-10-31, 5 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $191.13M.
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
